Predict your next investment


See what CB Insights has to offer



Date of IPO


Market Cap


About Sixth Wave Innovations

Sixth Wave Innovations (OTC:ATURF) is a nanotechnology company focused on CBD THC Isolates and Distillates Hemp.

Sixth Wave Innovations Headquarter Location

210 Waterfront Drive

British Columbia,


Latest Sixth Wave Innovations News

Sixth Wave Advances AMIPs(TM) With Saliva Testing

Dec 2, 2021

By Reading Time: 3 minutes Halifax, Nova Scotia–(Newsfile Corp. – December 2, 2021) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the “Company”) is pleased to announce the commencement of LIVE VIRUS testing in saliva samples using its patent-pending Accelerated Molecularly Imprinted Polymer (“AMIPs™”) technology relative to SARS-CoV-2 and variants of concern. The Company along with researchers at the La Ki Shing Institute of Virology are currently testing with AMIPs™ using saliva samples spiked with live SARS-CoV-2 virus by using a protocol similar to an ELISA clinical test. Confirmation studies, as well as additional advanced manufacturing techniques to increase sensitivity levels, are ongoing. These new techniques will simplify test analysis and should lead to further improvements in sensitivity and rejection of interferent molecules that are present in complex saliva samples and other sample collection methods. This phase of the development is expected to be completed later this month. AMIPs – Next Steps Viral selectivity screening is the next and final stage of laboratory-based development and will involve testing against a standardized panel of respiratory viruses to confirm that there is no cross-reactivity. Completion of the cross-reactivity testing is the last scientific development step required to produce specificity data before the Company can begin the process of applying for regulatory approval from government agencies such as the FDA and Health Canada. The Company is positioning itself to begin production of product prototypes in the first half of 2022 pending completion of this step. The Company expects to complete the current phase of testing in the coming weeks, with a successful outcome leading to validation testing by 3rd party laboratories. This testing will continue during the cross-reactivity testing and ultimately will progress to clinical trials with the pre-production prototypes as the Company moves toward submission of AMIPs™ and testing data to regulatory bodies for use authorization. Regulatory approval can be a time-intensive process but the Company believes that AMIPs™ represents a paradigm shift in testing. To date, AMIPs™ have proven very robust in the detection of variants and by design should continue to be relatively unaffected by mutations. AMIPs™ is completely synthetic eliminating major bottlenecks in raw materials, supply chain difficulties, handling limitations, nasal swabs, and waste products. Nothing about the design or manufacturing requirements identified to date suggests that AMIPs™ tests can’t be produced at or below the costs of similar ELISA or antigen tests. The Company is not making any express or implied claims that its current AMIPs™ product has the ability to eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time. For more information on the AMIPs™ and associated molecular imprinting technology, please visit: . About Sixth Wave Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label. Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development. For more information about Sixth Wave, please visit our website at: ON BEHALF OF THE BOARD OF DIRECTORS “Jonathan Gluckman”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Sixth Wave Innovations Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sixth Wave Innovations Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.